Clear Search

Showing 2 result for “Pina Vegas L”.

November 2022

JAK阻害薬とアダリムマブで治療された関節リウマチ患者の主要心血管イベントと静脈血栓のリスク: ナショナルコホート

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222824

Real-world population study of patients with RA provides reassuring data regarding the risks of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) in patients initiating a JAKinib versus adalimumab, including patients at high risk of cardiovascular diseases.


May 2022

乾癬性関節炎で生物学的製剤またはアプレミラストを 開始した患者の主要心血管イベントシルク: ナショナル レジストリ

doi: 10.1093/rheumatology/keab522

Pina Vegas and her colleagues sought to assess the relative risk of MACEs in patients with PsA initiating bDMARDs or apremilast. They found that overall, the data produced overall a positive picture regarding the incidence of MACE in treatment.